Marker Therapeutics (NASDAQ:MRKR) Stock Rating Lowered by Wall Street Zen

Marker Therapeutics (NASDAQ:MRKR) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Several other research firms have also recently commented on MRKR. Zacks Research upgraded Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Marker Therapeutics in a report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.25.

Marker Therapeutics Trading Down 4.8%

Shares of NASDAQ MRKR opened at $1.18 on Friday. The company has a fifty day moving average price of $1.00 and a 200 day moving average price of $1.21. The firm has a market cap of $19.67 million, a PE ratio of -0.96 and a beta of 1.35. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $5.95.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.57. The firm had revenue of $1.23 million for the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%. Equities research analysts forecast that Marker Therapeutics will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Marker Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP bought a new stake in Marker Therapeutics in the third quarter valued at approximately $33,000. Virtu Financial LLC bought a new stake in Marker Therapeutics in the 3rd quarter valued at $25,000. Finally, Jane Street Group LLC acquired a new stake in Marker Therapeutics during the 2nd quarter valued at $33,000. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.